The most practical approach for many patients is a hybrid: use standard titration to reach goal weight, then taper to the lowest effective dose for maintenance
The landmark SURMOUNT-1 trial followed participants for 72 weeks (approximately 18 months), demonstrating continued weight reduction throughout the study period
Additionally, other studies have found an elevated risk of thyroid cancer in GLP-1RA users (odds ratio 1.58), further emphasizing the need for careful patient selection
Quick response, great customer service and the product worked incredibly
Skriver C, Friis S, Knudsen LB, Catarig A-M, Clark AJ, Dehlendorff C, et al
The blood pressure benefits emerge through several interconnected pathways